A prognostic matrix code defines functional glioblastoma phenotypes and niches
暂无分享,去创建一个
R. Rostomily | O. Babur | Anil Korkut | Xubin Li | Zheng Yin | K. Yun | B. Bozorgui | Z. Dereli | Monika Vishnoi | M. Kinali | Nourhan Abdelfattah | Elisabeth K. Kong | Kisan Thapa | Kyuson Yun | Meric Kinali
[1] M. J. van den Bent,et al. Transcriptome analysis reveals tumor microenvironment changes in glioblastoma. , 2023, Cancer cell.
[2] E. Yeini,et al. 3D bioprinted cancer models: from basic biology to drug development , 2022, Nature Reviews Cancer.
[3] Xiaoxun Xie,et al. High Expression of Fibronectin 1 Predicts a Poor Prognosis in Glioblastoma , 2022, Current Medical Science.
[4] S. Marie,et al. Correlation of Matrisome-Associatted Gene Expressions with LOX Family Members in Astrocytomas Stratified by IDH Mutation Status , 2022, International journal of molecular sciences.
[5] Lucy F. Stead,et al. Glioma progression is shaped by genetic evolution and microenvironment interactions , 2022, Cell.
[6] Jennie W. Taylor,et al. Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter , 2022, Neuro-oncology.
[7] Mohd Nazmul Hasan Apu,et al. Multi-omics analysis predicts fibronectin 1 as a prognostic biomarker in glioblastoma multiforme. , 2022, Genomics.
[8] Betty Y. S. Kim,et al. Single-cell analysis of human glioma and immune cells identifies S100A4 as an immunotherapy target , 2022, Nature communications.
[9] J. Zaia,et al. In-Depth Matrisome and Glycoproteomic Analysis of Human Brain Glioblastoma Versus Control Tissue , 2022, Molecular & cellular proteomics : MCP.
[10] Chuanbao Zhang,et al. CTLA4-Mediated Immunosuppression in Glioblastoma is Associated with the Infiltration of Macrophages in the Tumor Microenvironment , 2021, Journal of inflammation research.
[11] A. Luna,et al. Mapping the functional interactions at the tumor-immune checkpoint interface , 2021, bioRxiv.
[12] K. Drummond,et al. Pretreatment neutrophil-to-lymphocyte/monocyte-to-lymphocyte ratio as prognostic biomarkers in glioma patients , 2021, Journal of Neuroimmunology.
[13] W. Guan,et al. Extracellular Matrix Characterization in Gastric Cancer Helps to Predict Prognosis and Chemotherapy Response , 2021, Frontiers in Oncology.
[14] M. Gumbleton,et al. Caveolin-1, a Key Mediator Across Multiple Pathways in Glioblastoma and an Independent Negative Biomarker of Patient Survival , 2021, Frontiers in Oncology.
[15] Z. Ram,et al. Microengineered perfusable 3D-bioprinted glioblastoma model for in vivo mimicry of tumor microenvironment , 2021, Science Advances.
[16] Yihan Yao,et al. Crosstalk Between Tumor-Associated Microglia/Macrophages and CD8-Positive T Cells Plays a Key Role in Glioblastoma , 2021, Frontiers in Immunology.
[17] S. Hautaniemi,et al. Co-evolution of matrisome and adaptive adhesion dynamics drives ovarian cancer chemoresistance , 2021, Nature Communications.
[18] A. Regev,et al. Interactions between cancer cells and immune cells drive transitions to mesenchymal-like states in glioblastoma. , 2021, Cancer cell.
[19] N. Matsumura,et al. Tumor Immune Microenvironment during Epithelial–Mesenchymal Transition , 2021, Clinical Cancer Research.
[20] S. Ricard-Blum,et al. A guide to the composition and functions of the extracellular matrix , 2021, The FEBS journal.
[21] G. Zadeh,et al. Lessons learned from contemporary glioblastoma randomized clinical trials through systematic review and network meta-analysis: part 1 newly diagnosed disease , 2021, Neuro-oncology advances.
[22] Joshua F. McMichael,et al. Proteogenomic and metabolomic characterization of human glioblastoma. , 2021, Cancer cell.
[23] Insuk Lee,et al. Systems biology analysis identifies TNFRSF9 as a functional marker of tumor-infiltrating regulatory T-cell enabling clinical outcome prediction in lung cancer , 2021, Computational and structural biotechnology journal.
[24] J. Mandell,et al. A patient-designed tissue-engineered model of the infiltrative glioblastoma microenvironment , 2020, bioRxiv.
[25] Z. Shao,et al. Natural killer cells in cancer biology and therapy , 2020, Molecular Cancer.
[26] S. Heiland,et al. Tumor cell plasticity, heterogeneity, and resistance in crucial microenvironmental niches in glioma , 2020, Nature Communications.
[27] Megan L. Wojciechowicz,et al. Genetic driver mutations introduced in identical cell-of-origin in murine glioblastoma reveal distinct immune landscapes but similar response to checkpoint blockade. , 2020, Glia.
[28] H. Friedman,et al. Management of glioblastoma: State of the art and future directions. , 2020, CA: a cancer journal for clinicians.
[29] Y. Ke,et al. High expression of stromal signatures correlated with macrophage infiltration, angiogenesis and poor prognosis in glioma microenvironment , 2020, PeerJ.
[30] A.D Rodriguez,et al. A Microfluidic Platform for Functional Testing of Cancer Drugs on Intact Tumor Slices , 2020, bioRxiv.
[31] A. Folch,et al. Multiplexed drug testing of tumor slices using a microfluidic platform , 2020, bioRxiv.
[32] A. Pearson,et al. A conserved intratumoral regulatory T cell signature identifies 4-1BB as a pan-cancer target. , 2020, The Journal of clinical investigation.
[33] S. Ergün,et al. Extracellular Matrix in the Tumor Microenvironment and Its Impact on Cancer Therapy , 2020, Frontiers in Molecular Biosciences.
[34] J. Erler,et al. Framing cancer progression: influence of the organ‐ and tumour‐specific matrisome , 2020, The FEBS journal.
[35] Kongming Wu,et al. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4 , 2019, Molecular Cancer.
[36] H. Wakimoto,et al. Identification of SERPINE1 as a Regulator of Glioblastoma Cell Dispersal with Transcriptome Profiling , 2019, Cancers.
[37] D. Steindler,et al. 3D extracellular matrix microenvironment in bioengineered tissue models of primary pediatric and adult brain tumors , 2019, Nature Communications.
[38] M. Shaul,et al. Tumour-associated neutrophils in patients with cancer , 2019, Nature Reviews Clinical Oncology.
[39] D. Brat,et al. Human Mesenchymal glioblastomas are characterized by an increased immune cell presence compared to Proneural and Classical tumors , 2019, Oncoimmunology.
[40] Yiling Lu,et al. TCPA v3.0: An Integrative Platform to Explore the Pan-Cancer Analysis of Functional Proteomic Data* , 2019, Molecular & Cellular Proteomics.
[41] Swee Jin Tan,et al. Pan-cancer analysis connects tumor matrisome to immune response , 2019, npj Precision Oncology.
[42] G. Riggins,et al. Correlation of the invasive potential of glioblastoma and expression of caveola-forming proteins caveolin-1 and CAVIN1 , 2019, Journal of Neuro-Oncology.
[43] P. Wen,et al. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma , 2018, Nature Medicine.
[44] Veerabhadran Baladandayuthapani,et al. Personalized Integrated Network Modeling of the Cancer Proteome Atlas , 2018, Scientific Reports.
[45] Shasha Liu,et al. Large-scale analysis reveals the specific clinical and immune features of B7-H3 in glioma , 2018, Oncoimmunology.
[46] Zhongming Zhao,et al. Subtype-specific signaling pathways and genomic aberrations associated with prognosis of glioblastoma , 2018, Neuro-oncology.
[47] Fuhui Long,et al. An anatomic transcriptional atlas of human glioblastoma , 2018, Science.
[48] Zhihong Chen,et al. Immune Microenvironment in Glioblastoma Subtypes , 2018, Front. Immunol..
[49] Peter W. Laird,et al. Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer , 2018, Cell.
[50] Steven J. M. Jones,et al. The Immune Landscape of Cancer , 2018, Immunity.
[51] K. Makino,et al. Oligodendrocyte Progenitor Cells and Macrophages/Microglia Produce Glioma Stem Cell Niches at the Tumor Border , 2018, EBioMedicine.
[52] J. Yang,et al. CD70, a novel target of CAR T-cell therapy for gliomas , 2018, Neuro-oncology.
[53] F. Lieberman,et al. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial , 2017, JAMA.
[54] Martin Klein,et al. Lomustine and Bevacizumab in Progressive Glioblastoma , 2017, The New England journal of medicine.
[55] Betty Y. S. Kim,et al. S100A4 Is a Biomarker and Regulator of Glioma Stem Cells That Is Critical for Mesenchymal Transition in Glioblastoma. , 2017, Cancer research.
[56] R. Hynes,et al. Characterization of the Extracellular Matrix of Normal and Diseased Tissues Using Proteomics. , 2017, Journal of proteome research.
[57] Edward F. Chang,et al. Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment. , 2017, Cancer cell.
[58] In-Hee Lee,et al. Spatiotemporal genomic architecture informs precision oncology in glioblastoma , 2017, Nature Genetics.
[59] Katrina Stevenson,et al. A novel 3D human glioblastoma cell culture system for modeling drug and radiation responses , 2016, Neuro-oncology.
[60] R. Stupp,et al. Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome , 2016, Oncotarget.
[61] A. Giordano,et al. Glioblastoma Stem Cells Microenvironment: The Paracrine Roles of the Niche in Drug and Radioresistance , 2016, Stem cells international.
[62] Thomas C. Chen,et al. Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. , 2015, JAMA.
[63] Jaime Rodriguez-Canales,et al. A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition , 2015, Clinical Cancer Research.
[64] S. Carr,et al. The extracellular matrix: Tools and insights for the "omics" era. , 2015, Matrix biology : journal of the International Society for Matrix Biology.
[65] Emily J. Girard,et al. Deep sequencing of multiple regions of glial tumors reveals spatial heterogeneity for mutations in clinically relevant genes , 2014, Genome Biology.
[66] B. Langlois,et al. AngioMatrix, a signature of the tumor angiogenic switch-specific matrisome, correlates with poor prognosis for glioma and colorectal cancer patients , 2014, Oncotarget.
[67] Shawn M. Gillespie,et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma , 2014, Science.
[68] Prahlad T. Ram,et al. A pan-cancer proteomic perspective on The Cancer Genome Atlas , 2014, Nature Communications.
[69] Jingchun Zhu,et al. Realizing the Promise of Reverse Phase Protein Arrays for Clinical, Translational, and Basic Research: A Workshop Report , 2014, Molecular & Cellular Proteomics.
[70] G. Fuller,et al. Neutrophils Promote the Malignant Glioma Phenotype through S100A4 , 2013, Clinical Cancer Research.
[71] Walter J Curran,et al. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[72] Christina S. Leslie,et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression , 2013, Nature Medicine.
[73] Jun Li,et al. TCPA: a resource for cancer functional proteomics data , 2013, Nature Methods.
[74] Demin Li,et al. A Core Human Primary Tumor Angiogenesis Signature Identifies the Endothelial Orphan Receptor ELTD1 as a Key Regulator of Angiogenesis , 2013, Cancer cell.
[75] Mohammad Kohandel,et al. Investigating the Link between Molecular Subtypes of Glioblastoma, Epithelial-Mesenchymal Transition, and CD133 Cell Surface Protein , 2013, PloS one.
[76] Michael Peyton,et al. An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance , 2012, Clinical Cancer Research.
[77] Benjamin E. Gross,et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.
[78] Koji Kadota,et al. A normalization strategy for comparing tag count data , 2012, Algorithms for Molecular Biology.
[79] Steven A. Carr,et al. The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices , 2011, Molecular & Cellular Proteomics.
[80] S. Gabriel,et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.
[81] C. Brennan,et al. Glioblastoma Subclasses Can Be Defined by Activity among Signal Transduction Pathways and Associated Genomic Alterations , 2009, PloS one.
[82] Joshua M. Korn,et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.
[83] Thomas D. Wu,et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. , 2006, Cancer cell.
[84] Martin J. van den Bent,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.
[85] H. Rammensee,et al. Identification of CD70-mediated apoptosis of immune effector cells as a novel immune escape pathway of human glioblastoma. , 2002, Cancer research.
[86] Alexandra Naba,et al. Overview of the matrisome--an inventory of extracellular matrix constituents and functions. , 2012, Cold Spring Harbor perspectives in biology.